Answers are grounded in this paper and cite their sources.
One of the most difficult and significant aspects in clinical pharmacology is the issue of pain management. Opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and adjuvant analgesics are a large group of drugs that have various physical and chemical characteristics that influence their pharmacokinetic activity and pharmacodynamic response. This paper is an extensive overview of the structural features, physicochemical data (such as lipophilicity, pKa, protein binding, and permeability of the blood-brain barrier), and molecular action of some examples of analgesic agents. Special attention has been given to the opioid subgroup, where the example of oxycodone was used as a model case study in which minor structural changes, namely the 3-methoxy group and 14-hydroxy substitution, resulted in different metabolic pathways (CYP3A4- and CYP2D6-mediated), greater oral bioavailability, and unique kinetics of receptor-binding when compared to morphine. In addition to the discussion of non-opioid analgesics such as COX inhibitors and voltage-gated ion channel modulators, the structure-activity relationships are discussed. Moreover, the effects of drug-drug interactions on analgesic therapy of analgesia, pharmacogenetics (e.g., poor metabolizer phenotypes of CYP2D6), and new approaches to the optimization of analgesic treatment were also considered. This compilation will be helpful in providing a structured source of information about how therapeutic effects are determined by the properties of physicochemical properties and what should be done next to develop drugs.
No takes yet. Share an insight, caveat, or question.
Yuze Li (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: